Biotest Aktiengesellschaft (FRA:BIO)
Germany
· Delayed Price · Currency is EUR 42.60
0.00 (0.00%)
At close: May 9, 2025, 10:00 PM CET
FRA:BIO Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 635.2 | 726.2 | 684.6 | 516.1 | 515.6 | 484.2 | Upgrade
|
| Revenue Growth (YoY) | -18.83% | 6.08% | 32.65% | 0.10% | 6.49% | 15.53% | Upgrade
|
| Cost of Revenue | 487.9 | 502.4 | 404.3 | 391.2 | 434.9 | 354.1 | Upgrade
|
| Gross Profit | 147.3 | 223.8 | 280.3 | 124.9 | 80.7 | 130.1 | Upgrade
|
| Selling, General & Admin | 88.7 | 91.3 | 84.4 | 81.9 | 82 | 79.5 | Upgrade
|
| Research & Development | 56.9 | 56.8 | 66.8 | 50.5 | 52.3 | 55.8 | Upgrade
|
| Other Operating Expenses | -2.4 | -3.2 | 12.5 | 12.7 | -2.7 | 2.4 | Upgrade
|
| Operating Expenses | 135.3 | 137 | 163.6 | 145.1 | 131.6 | 137.7 | Upgrade
|
| Operating Income | 12 | 86.8 | 116.7 | -20.2 | -50.9 | -7.6 | Upgrade
|
| Interest Expense | -29.9 | -30.3 | -36.6 | -18.5 | -12.4 | -13.1 | Upgrade
|
| Interest & Investment Income | 2 | 2 | 2 | 0.8 | 0.2 | 1.2 | Upgrade
|
| Earnings From Equity Investments | -4.4 | -4.4 | 2.8 | -1 | 1.3 | -0.5 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.1 | -1.1 | -0.8 | 0.2 | -0.4 | -5.4 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.9 | -1.4 | -0.3 | -2.9 | -2.3 | -9.8 | Upgrade
|
| EBT Excluding Unusual Items | -19.5 | 51.6 | 83.8 | -41.6 | -64.5 | -35.2 | Upgrade
|
| Gain (Loss) on Sale of Investments | -9.7 | -9.7 | -0.9 | 8.4 | -1.2 | - | Upgrade
|
| Other Unusual Items | 3.8 | 3.8 | 23.2 | 1.1 | 1.1 | 5 | Upgrade
|
| Pretax Income | -25.6 | 46.6 | 106.3 | -30.9 | -62.7 | -30 | Upgrade
|
| Income Tax Expense | -1.1 | 20.2 | -20.7 | 0.8 | 0.7 | 1.4 | Upgrade
|
| Earnings From Continuing Operations | -24.5 | 26.4 | 127 | -31.7 | -63.4 | -31.4 | Upgrade
|
| Net Income to Company | -24.5 | 26.4 | 127 | -31.7 | -63.4 | -31.4 | Upgrade
|
| Net Income | -24.5 | 26.4 | 127 | -31.7 | -63.4 | -31.4 | Upgrade
|
| Net Income to Common | -24.5 | 26.4 | 127 | -31.7 | -63.4 | -31.4 | Upgrade
|
| Net Income Growth | - | -79.21% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 39 | 40 | 40 | 40 | 40 | 40 | Upgrade
|
| Shares Outstanding (Diluted) | 39 | 40 | 40 | 40 | 40 | 40 | Upgrade
|
| EPS (Basic) | -0.62 | 0.67 | 3.21 | -0.80 | -1.60 | -0.79 | Upgrade
|
| EPS (Diluted) | -0.63 | 0.66 | 3.20 | -0.80 | -1.60 | -0.79 | Upgrade
|
| EPS Growth | - | -79.38% | - | - | - | - | Upgrade
|
| Free Cash Flow | -14.3 | 32.2 | -36.1 | -69.8 | 15.6 | -43.7 | Upgrade
|
| Free Cash Flow Per Share | -0.36 | 0.81 | -0.91 | -1.76 | 0.39 | -1.10 | Upgrade
|
| Dividend Per Share | 0.040 | 0.040 | 0.040 | - | 0.040 | 0.040 | Upgrade
|
| Gross Margin | 23.19% | 30.82% | 40.94% | 24.20% | 15.65% | 26.87% | Upgrade
|
| Operating Margin | 1.89% | 11.95% | 17.05% | -3.91% | -9.87% | -1.57% | Upgrade
|
| Profit Margin | -3.86% | 3.64% | 18.55% | -6.14% | -12.30% | -6.49% | Upgrade
|
| Free Cash Flow Margin | -2.25% | 4.43% | -5.27% | -13.53% | 3.03% | -9.03% | Upgrade
|
| EBITDA | 46.78 | 120.7 | 147.1 | 10.4 | -24.8 | 17.3 | Upgrade
|
| EBITDA Margin | 7.36% | 16.62% | 21.49% | 2.02% | -4.81% | 3.57% | Upgrade
|
| D&A For EBITDA | 34.78 | 33.9 | 30.4 | 30.6 | 26.1 | 24.9 | Upgrade
|
| EBIT | 12 | 86.8 | 116.7 | -20.2 | -50.9 | -7.6 | Upgrade
|
| EBIT Margin | 1.89% | 11.95% | 17.05% | -3.91% | -9.87% | -1.57% | Upgrade
|
| Effective Tax Rate | - | 43.35% | - | - | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.